{"id":797956,"date":"2025-01-06T08:18:24","date_gmt":"2025-01-06T13:18:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/"},"modified":"2025-01-06T08:18:24","modified_gmt":"2025-01-06T13:18:24","slug":"sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/","title":{"rendered":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference"},"content":{"rendered":"
\n

SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th<\/sup> Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2\/F3 MASH.<\/p>\n

\n MASH-TAG 2025 Presentation Details<\/strong>:<\/p>\n\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nFASN Inhibitors<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nMarie O\u2019Farrell, Ph.D. (SVP of Research and Development, Sagimet Biosciences)<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nSession 4: The Promise of New Pharmacological Agents + Pathophysiology<\/td>\n<\/tr>\n
\n Date\/Time:<\/strong>\n <\/td>\nFriday, January 10, 2025 at 6:10 PM MST<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nThe Chateaux Deer Valley, Park City, Utah<\/td>\n<\/tr>\n<\/table>\n

\n
\n
About Sagimet Biosciences <\/strong>\n <\/p>\n

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet\u2019s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com<\/a>.<\/p>\n

\n About MASH <\/strong>\n <\/p>\n

Metabolic dysfunction associated steatohepatitis (MASH) is a progressive and severe liver disease which is estimated to impact more than 115 million people worldwide, for which there is only one recently approved treatment in the United States and no currently approved treatments in Europe. In 2023, global liver disease medical societies and patient groups formalized the decision to rename non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. The goal of the name change was to establish an affirmative, non-stigmatizing name and to improve diagnostic clarity.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet\u2019s clinical development plans and related anticipated development milestones, Sagimet\u2019s cash and financial resources and expected cash runway. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201caim,\u201d \u201cseek,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions.<\/p>\n

The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet\u2019s control, including, among others: the clinical development and therapeutic potential of denifanstat or any other drug candidates Sagimet may develop; Sagimet\u2019s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines, including its Phase 3 denifanstat program; Sagimet\u2019s relationship with\u00a0Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet\u2019s estimates regarding its capital requirements; and Sagimet\u2019s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the \u201cRisk Factors\u201d section of Sagimet\u2019s most recent filings with the\u00a0Securities and Exchange Commission\u00a0and available at\u00a0www.sec.gov<\/a>. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n

Contact:
Joyce Allaire\u00a0
LifeSci Advisors\u00a0
jallaire@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2\/F3 MASH. MASH-TAG 2025 Presentation Details: Title: FASN Inhibitors Presenter: Marie O\u2019Farrell, Ph.D. (SVP of Research and Development, Sagimet Biosciences) Session: Session 4: The Promise of New Pharmacological Agents + Pathophysiology Date\/Time: Friday, January … <\/p>\n

Continue reading “Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-797956","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2\/F3 MASH. MASH-TAG 2025 Presentation Details: Title: FASN Inhibitors Presenter: Marie O\u2019Farrell, Ph.D. (SVP of Research and Development, Sagimet Biosciences) Session: Session 4: The Promise of New Pharmacological Agents + Pathophysiology Date\/Time: Friday, January … Continue reading "Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-06T13:18:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference\",\"datePublished\":\"2025-01-06T13:18:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/\"},\"wordCount\":888,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/\",\"name\":\"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=\",\"datePublished\":\"2025-01-06T13:18:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/","og_locale":"en_US","og_type":"article","og_title":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - Market Newsdesk","og_description":"SAN MATEO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting fatty acid synthase (FASN) inhibitors will be given at the upcoming 9th Annual MASH-TAG Conference being held January 9-11, 2025 in Park City, Utah. The presentation will focus on the differentiated mechanism of action of the FASN inhibitor denifanstat and the observed anti-fibrotic effect in the Phase 2b FASCINATE-2 study in F2\/F3 MASH. MASH-TAG 2025 Presentation Details: Title: FASN Inhibitors Presenter: Marie O\u2019Farrell, Ph.D. (SVP of Research and Development, Sagimet Biosciences) Session: Session 4: The Promise of New Pharmacological Agents + Pathophysiology Date\/Time: Friday, January … Continue reading \"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-06T13:18:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference","datePublished":"2025-01-06T13:18:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/"},"wordCount":888,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/","name":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=","datePublished":"2025-01-06T13:18:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzY0MSM2NjcwMDc5IzIyMDg2NDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sagimet-biosciences-announces-oral-presentation-at-the-9th-annual-mash-tag-2025-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=797956"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=797956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=797956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=797956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}